Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after treatment, finds a trial published ...
Nov 23, 2022
0
33
A team of researchers affiliated with multiple institutions in Australia and the U.S. has found that taking an aspirin a day does not lower the risk of bone fractures in healthy older people. In their paper published in JAMA ...
Six widely used dietary supplements promoted for improving heart health did not effectively lower LDL or "bad" cholesterol in comparison to a common low-dose statin medication or placebo, according to late breaking science ...
Nov 7, 2022
1
77
A phase I/IIa clinical trial that the University of Oxford collaborated on has demonstrated that a T-cell therapeutic HIV vaccine was associated with better control of the virus rebound when antiretroviral therapy (ART) was ...
Nov 4, 2022
0
33
Partner companies Eisai and Biogen recently announced promising clinical trial results for their new Alzheimer's drug lecanemab. Over 18 months, patients treated with lecanemab experienced slower symptom progression than ...
Oct 14, 2022
0
5
For children with acute infective conjunctivitis, topical antibiotics are associated with a shorter duration of conjunctival symptoms, according to a study published online Oct. 4 in JAMA Network Open.
Oct 4, 2022
0
5
Early intervention with rituximab, a drug used in the treatment of rheumatoid arthritis (RA), can reduce the risk of deterioration in myasthenia gravis, an autoimmune disease that causes loss of muscle control. This is according ...
Sep 19, 2022
0
48
When the menopause sets in, many women consider initiating hormonal therapy containing the sex hormone estrogen.
Sep 12, 2022
0
20
Significant improvement in progression free survival and response rate combined with reduced symptoms and better quality of life are reported as outcomes of a new treatment approach for patients with desmoid tumors, which ...
Sep 12, 2022
0
4
The PACIFIC-Stroke trial has failed to reach its primary endpoint but in an exploratory analysis, inhibition of factor XIa with asundexian reduced recurrent ischemic stroke and transient ischemic attack (TIA) without increasing ...
Aug 29, 2022
0
4
